“ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING”. Mediterranean Journal of Hematology and Infectious Diseases 10, no. 1 (February 15, 2018): e2018014. Accessed May 2, 2026. https://www.mjhid.org/mjhid/article/view/2018.014.